---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-057112"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2026-08-14T20:09:44+00:00"
generated_at: "2026-08-14T20:18:04.571487+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Zentalis prices 23M-share offering at $3.50, netting ~$75.1M

## Summary
- Offering of 23,000,000 shares at $3.50/share; underwriters have 30-day option for 3,450,000 additional shares.
- Net proceeds estimated at $75.1M after underwriting discounts and offering expenses.
- Closing expected August 17, 2026, subject to customary conditions.
- Proceeds to fund clinical trials, preclinical studies, regulatory filings, manufacturing, companion diagnostic, pre-commercial activities, and general corporate purposes.
- Underwriters: TD Securities, Guggenheim Securities, and Oppenheimer & Co. as representatives.

## SEC filing metadata
- accession: 0001628280-26-057112
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2026-08-14T20:09:44+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000162828026057112/0001628280-26-057112-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000162828026057112/zntl-20260813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-057112
- JSON: https://secwatch.observer/filing/0001628280-26-057112.json
- Plain text: https://secwatch.observer/filing/0001628280-26-057112.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.